The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India 1 , 2 , 3 , 4 – 5 .
Since then, it has become dominant in some regions of India and in the UK, and has spread to …

Broadly neutralizing HIV antibodies (bNAbs) can recognize carbohydrate-dependent epitopes
on gp120. In contrast to previously characterized glycan-dependent bNAbs that recognize …

The SARS-CoV-2 Omicron variant was first identified in November 2021 in Botswana and
South Africa 1 , 2 – 3 . It has since spread to many countries and is expected to rapidly become …

It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic
cases of SARS-CoV-2 infection and their differing antibody response profiles. Here, we …

Antibodies to conserved epitopes on the human immunodeficiency virus (HIV) surface protein
gp140 can protect against infection in non-human primates, and some infected individuals …

Background The combination of multiple cycles of rituximab and intravenous immune
globulins has been reported to be effective in patients with severe pemphigus. The aim of this …

During immune responses, antibodies are selected for their ability to bind to foreign antigens
with high affinity, in part by their ability to undergo homotypic bivalent binding. However, …

B cells express immunoglobulins on their surface where they serve as antigen receptors.
When secreted as antibodies, the same molecules are key elements of the humoral immune …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.7 and B.1.351 variants
were first identified in the United Kingdom and South Africa, respectively, and have since …

Passive transfer of broadly neutralizing HIV antibodies can prevent infection, which suggests
that vaccines that elicit such antibodies would be protective. Thus far, however, few broadly …